Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glubran 2 is a synthetic surgical glue and hemostatic agent composed of two monomers: n-butyl-2-cyanoacrylate (NBCA) and methacryloxysulfolane (MS). When it comes into contact with living tissue or moist environments containing ions, the monomers undergo a rapid exothermic polymerization reaction, creating a thin, elastic film with high tensile strength that adheres firmly to tissues. The inclusion of methacryloxysulfolane is a key modification that allows polymerization to occur at a lower temperature (approximately 45°C) compared to pure NBCA glues, reducing tissue thermal damage while providing greater flexibility to the resulting polymer. This combination is used for a variety of indications including hemostasis, tissue sealing, and wound closure across surgical, endoscopic, and endovascular procedures. It also possesses bacteriostatic properties that help prevent surgical site infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Glubran 2 (Gem).